XML 101 R89.htm IDEA: XBRL DOCUMENT v3.21.1

SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 2,027	$ 2,012
Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	896	939
Devices
Disaggregation of Revenue [Line Items]
Revenues	454	392
OTC
Disaggregation of Revenue [Line Items]
Revenues	343	349
Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	310	306
Other revenues
Disaggregation of Revenue [Line Items]
Revenues	24	26
Bausch + Lomb
Disaggregation of Revenue [Line Items]
Revenues	881	875
Bausch + Lomb | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	125	138
Bausch + Lomb | Devices
Disaggregation of Revenue [Line Items]
Revenues	382	341
Bausch + Lomb | OTC
Disaggregation of Revenue [Line Items]
Revenues	316	321
Bausch + Lomb | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	51	68
Bausch + Lomb | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	7	7
Salix
Disaggregation of Revenue [Line Items]
Revenues	472	477
Salix | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	470	477
Salix | Devices
Disaggregation of Revenue [Line Items]
Revenues	0	0
Salix | OTC
Disaggregation of Revenue [Line Items]
Revenues	0	0
Salix | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	0	0
Salix | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	2	0
International Rx
Disaggregation of Revenue [Line Items]
Revenues	306	291
International Rx | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	59	66
International Rx | Devices
Disaggregation of Revenue [Line Items]
Revenues	0	0
International Rx | OTC
Disaggregation of Revenue [Line Items]
Revenues	25	26
International Rx | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	212	188
International Rx | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	10	11
Ortho Dermatologics
Disaggregation of Revenue [Line Items]
Revenues	141	131
Ortho Dermatologics | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	65	76
Ortho Dermatologics | Devices
Disaggregation of Revenue [Line Items]
Revenues	72	51
Ortho Dermatologics | OTC
Disaggregation of Revenue [Line Items]
Revenues	0	0
Ortho Dermatologics | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	0	0
Ortho Dermatologics | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	4	4
Diversified Products
Disaggregation of Revenue [Line Items]
Revenues	227	238
Diversified Products | Pharmaceuticals
Disaggregation of Revenue [Line Items]
Revenues	177	182
Diversified Products | Devices
Disaggregation of Revenue [Line Items]
Revenues	0	0
Diversified Products | OTC
Disaggregation of Revenue [Line Items]
Revenues	2	2
Diversified Products | Branded and Other Generics
Disaggregation of Revenue [Line Items]
Revenues	47	50
Diversified Products | Other revenues
Disaggregation of Revenue [Line Items]
Revenues	$ 1	$ 4

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bhc_DeviceProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bhc_OtherRevenuesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: